Open access
Oct 2026
Real-world efficacy and safety of neoadjuvant immunochemotherapy in patients with triple-negative breast cancer.
Compared with NAC alone, NAIC significantly improves the pCR rate and reduces the recurrence risk in TNBC patients, with generally manageable toxicity in this real-world cohort, which supports its favorable clinical application value.
Ruo-Xi Xu, Pin-Chao Fan, Yi-Qiu Liu et al.
· Immunotherapy · 0 citations